

Caring for Patients with Genitourinary Malignancies

Katie Morgan PharmD and
Tracy Rose MD MPH

Division of Oncology
University of North Carolina at Chapel Hill




1

Objectives

- Understand the breadth of genitourinary malignancies
- Recognize the role of each multidisciplinary team member
- Learn the basics of each major type of GU cancer: prostate, bladder, kidney, and testis
- Review types of cancer treatments used in GU malignancies



2



3

Leading Causes of Death in the U.S.

- Heart disease: 635,206
- **Cancer: 598,038**
- Accidents (unintentional injuries): 161,374
- Chronic lower respiratory diseases: 154,596
- Stroke (cerebrovascular diseases): 142,142
- Alzheimer's disease: 116,103
- Diabetes: 80,058
- Influenza and Pneumonia: 51,537
- Nephritis, nephrotic syndrome and nephrosis: 50,046
- Intentional self-harm (suicide): 44,965



CDC.gov, accessed 10/12/18 UNC

4

Cancer Statistics

Estimated New Cases

| | Males | Females | | |
|--------------------------------|---------|---------|-----------------------|--------------|
| Prostate | 101,200 | 19% | Breast | 252,710 30% |
| Lung & bronchus | 116,900 | 14% | Lung & bronchus | 105,510 12% |
| Colon & rectum | 71,420 | 9% | Colon & rectum | 64,010 8% |
| Urinary bladder | 80,490 | 7% | Uterine corpus | 61,380 7% |
| Melanoma of the skin | 52,170 | 6% | Thyroid | 42,470 5% |
| Kidney & renal pelvis | 40,610 | 5% | Melanoma of the skin | 34,940 4% |
| Non-Hodgkin lymphoma | 40,080 | 5% | Non-Hodgkin lymphoma | 32,160 4% |
| Leukemia | 36,290 | 4% | Leukemia | 25,840 3% |
| Oral cavity & pharynx | 35,720 | 4% | Pancreas | 25,700 3% |
| Liver & intrahepatic bile duct | 29,200 | 3% | Kidney & renal pelvis | 23,380 3% |
| All Sites | 836,150 | 100% | All Sites | 852,630 100% |

FIGURE 1. Ten Leading Cancer Types for the Estimated New Cancer Cases and Deaths by Sex, United States, 2017. Estimates are rounded to the nearest 10 and cases exclude basal cell and squamous cell skin cancers and in situ carcinoma except urinary bladder.



Siegel, 2017 UNC

5

Cancer Statistics

Estimated Deaths

| | Males | Females | | |
|--------------------------------|---------|---------|--------------------------------|--------------|
| Lung & bronchus | 64,590 | 27% | Lung & bronchus | 71,280 29% |
| Colon & rectum | 27,150 | 9% | Breast | 40,610 14% |
| Prostate | 26,730 | 8% | Colon & rectum | 23,110 8% |
| Pancreas | 22,300 | 7% | Pancreas | 20,790 7% |
| Liver & intrahepatic bile duct | 19,610 | 6% | Ovary | 14,080 5% |
| Leukemia | 14,300 | 4% | Uterine corpus | 10,920 4% |
| Esophagus | 12,720 | 4% | Leukemia | 10,200 4% |
| Urinary bladder | 12,240 | 4% | Liver & intrahepatic bile duct | 9,310 3% |
| Non-Hodgkin lymphoma | 11,450 | 4% | Non-Hodgkin lymphoma | 8,690 3% |
| Brain & other nervous system | 9,620 | 3% | Brain & other nervous system | 7,080 3% |
| All Sites | 318,420 | 100% | All Sites | 282,500 100% |

FIGURE 1. Ten Leading Cancer Types for the Estimated New Cancer Cases and Deaths by Sex, United States, 2017. Estimates are rounded to the nearest 10 and cases exclude basal cell and squamous cell skin cancers and in situ carcinoma except urinary bladder.



Siegel, 2017 UNC

6

Most Common GU Cancers

- Prostate
- Bladder
- Kidney
- Testis (germ cell tumors)




7



8

Prostate Cancer

Prostate cancer is a disease in which malignant (cancer) cells form in the prostate gland



<https://www.cancer.org/cancer/prostate-cancer/about/what-is-prostate-cancer.html>



9

Physiology of Prostate Cancer

- Partly glandular and muscular organ within lower pelvis
- Accessory reproductive gland
- Secretes alkaline fluid that forms a part of the ejaculate which aids in motility and nourishment of sperm
- 4 zones: peripheral (75%), central, transition, fibromuscular
- Size of a walnut in young men, but grows with age



10

Pathophysiology of Prostate Cancer

- ~90% are adenocarcinomas (formed from the gland cells)
 - Remaining ~10% are primarily neuroendocrine
- Typically spreads first to lymph nodes
- Metastasis = distant spread outside the prostate
 - Bone most common
 - Distant lymph nodes
 - Organs less common – and a bad sign!
- Commonly diagnosed by digital rectal exam or PSA



11

Clinical Presentation


- **Usually asymptomatic**
- Lower urinary tract symptoms (LUTS)
- Bony pain
- Renal failure
- Spinal cord compression



12

Diagnosis

- Shared decision making to screen
- PSA, DRE
- Prostate biopsy
 - Office procedure
 - transrectal ultrasound guided
 - 12 cores
 - Minor prep



13

Grade = measure of the microscopic appearance (ie, how much does it resemble normal prostate?)



Epstein, J. Prostate cancer grading: a decade after the 2005 modified system. *Mod Pathol* 31, 47–63 (2018). <https://doi.org/10.1038/modpathol.2017.133>



14

Cancer Staging

- Define as precisely as possible the **extent** of disease
- **Rationale:** Staging will determine
 - Treatment
 - Prognosis
 - Surveillance
- A common currency for reporting treatment results



15

Prostate Cancer Staging

| Group | T | N | M | PSA | Gleason |
|-------|-------|-------|----|------------|-------------|
| I | T1a-c | N0 | M0 | PSA <10 | Gleason ≤6 |
| | T2a | N0 | M0 | PSA <10 | Gleason < 6 |
| | T1-2a | N0 | M0 | PSA X | Gleason X |
| IIA | T1a-c | N0 | M0 | PSA <20 | Gleason 7 |
| | T1a-c | N0 | M0 | PSA ≥10-20 | Gleason ≤ 6 |
| | T2a | N0 | M0 | PSA <10-20 | Gleason ≤ 6 |
| | T2a | N0 | M0 | PSA <20 | Gleason 7 |
| | T2b | N0 | M0 | PSA <20 | Gleason ≤ 7 |
| | T2b | N0 | M0 | PSA X | Gleason X |
| IIB | T2c | N0 | M0 | Any PSA | Any Gleason |
| | T1-2 | N0 | M0 | PSA ≥ 20 | Any Gleason |
| | T1-2 | N0 | M0 | Any PSA | Gleason ≥ 8 |
| III | T3a-b | N0 | M0 | Any PSA | Any Gleason |
| IV | T4 | N0 | M0 | Any PSA | Any Gleason |
| | Any T | N1 | M0 | Any PSA | Any Gleason |
| | Any T | Any N | M1 | Any PSA | Any Gleason |




16

Principles of Treatment

Local

Surgery

Radiation

vs

Locoregional

Surgery

Radiation

vs

Systemic

Chemotherapy

Commonly we combine these approaches
= Multimodality treatment




17

Prostate Cancer Treatment

Active Surveillance

- Typical criteria: PSA <10, Gleason 6, Stage T1c-T2a, >10 yr life expectancy, low volume
- Follow up: PSA & DRE every 3-6 months, biopsy annually
- Intervention: Change on biopsy, concerning PSA trend
- Not appropriate for all men meeting criteria
- Other: Age, comorbidities, anxiety, commitment to follow up schedule




18

Prostate Cancer Treatment

Radical prostatectomy

- Surgical removal of the prostate gland and seminal vesicles
- Open, laparoscopic, robotic techniques
- Considerations: Age, comorbidities, prior abdominal surgeries
- 1 night in the hospital, leave with catheter
- Side effects: Erectile dysfunction, urine leakage, infertility
- Follow up: every 3 months x 1 year; every 6 months until year 5, annually until year 10




19

Prostate Cancer Treatment

Radiation Therapy

- Intensity Modulated Radiation Therapy: gives higher dose to prostate and less to surrounding tissue
- Uses a machine outside the body to deliver radiation
- Usually 5 days/week, 4-6 weeks
- If >intermediate risk disease will get hormone shots too
- Side effects: urinary symptoms, diarrhea, rectal irritation, fatigue, erectile dysfunction




20

Prostate Cancer Treatment

Brachytherapy

- Radioactive seeds implanted into the prostate
- Low risk disease; prostate size matters
- Side effects: Urinary retention, painful urination, erectile dysfunction




21


Prostate Cancer Treatment

Cryotherapy

- Surgical freezing of the prostate
- Causes cell death
- Candidates: Unfit for surgery or radiation
- Side effects: Erectile dysfunction (near 100%), rectal pain, urinary symptoms

High-intensity focused ultrasound (HIFU)

- Ablates tissue using heat
- Side effects: urinary symptoms, erectile dysfunction



22

Advanced Prostate Cancer Treatment


- Metastatic or stage IV prostate cancer is not curable
- Treatment focus is on prolonging as good a life as possible = PALLIATIVE
- Cornerstone of treatment is blocking the tumor's access to the male hormone testosterone – more to come!
- Also use standard chemotherapy



23

Bladder Cancer

- Typically diagnosed in 5th-7th decade
- Global disease: ~350,000 new cases/year
 - The most common GU cancer in China
- Non-muscle-invasive: 75% at presentation
- **Highest recurrence rate** of any cancer
 - Substantial burden of health services
- Comparatively poor research funding



<https://www.cancer.org/cancer/bladder-cancer/about/what-is-bladder-cancer.html>



24


Bladder Cancer – Risk Factors

- Male sex
- Cigarettes: 3x risk in current smokers
 - (50% reduction after quitting 5y)
 - Not just lung cancer
 - SMOKING CESSATION
- Family history and/or genetic mutations
- Age
- Chemical exposures
 - Aniline dye, gas/soot from coal, analgesic (phenacetin), dyes, rubber
 - Cyclophosphamide: Acrolein (urinary metabolite of Cytosan) can cause hemorrhagic cystitis. Latency period 6-13 years
 - Occupations: Textile workers, truckers, leather/dye workers, painters, hairdressers, dry cleaners
- Pelvic Radiation
- Chronic cystitis
 - Long term indwelling catheters, chronic UTI, stones, schistosoma haematobium



25

Bladder Cancer – Staging




- Presence, Depth of Invasion
- ~25% muscle-invasive at presentation
- “Superficial” → non-muscle invasive
 - T1: still invasive



26

Bladder Cancer Treatment – Non-muscle invasive



- Resect it via cystoscopy (via a camera in the bladder – “transurethral”)
- Sometimes put BCG (yes, like the TB vaccine) or other therapy directly into the bladder
- Emerging data on intravenous treatments to retrain the immune system



27

Bladder Cancer Treatment – Muscle-invasive

CIS Ta T1 T2 T3

Urothelium
Lamina Propria
Muscle
Fat

- A true multidisciplinary team approach
- Typically treat with chemotherapy followed by bladder removal ("cystectomy) or transurethral resection followed by chemotherapy plus radiation therapy

UNC
UNIVERSITY OF NORTH CAROLINA

28

Bladder Cancer Treatment – Cystectomy with Urinary Diversion

Ileal conduit Continent cutaneous diversion

Copyright 2007 by Saunders, an imprint of Elsevier Inc.

UNC
UNIVERSITY OF NORTH CAROLINA

29

Bladder Cancer Treatment – Ostomy Care

- Urinary diversion management
 - Skin irritation
 - Properly fitting appliance/leaking
 - Odor
 - Body image
 - Intimacy
 - Supplies
 - Consult WOCN

UNC
UNIVERSITY OF NORTH CAROLINA

30


Bladder Cancer Treatment – Advanced Disease

- Unresectable and metastatic bladder cancer remains incurable
- Chemotherapy historically was the cornerstone of treatment
- Finally some progress
 - 5 new immunotherapies, 1 targeted therapy, and 1 new “antibody-drug conjugate) approved in the last several years!
- Supportive care is crucial




31

Kidney Cancer




<https://www.cancer.org/cancer/kidney-cancer/about/what-is-kidney-cancer.html>




32

Kidney Cancer = not a single disease




| | | | | | |
|------|------------|------------------|------------------|-------------|------------|
| Type | Clear Cell | Papillary Type 1 | Papillary Type 2 | Chromophobe | Oncocytoma |
| | 75% | 5% | 10% | 5% | 5% |
| Gene | VHL | Met | FH | BHD | |

W. Marston Linehan et al. Clin Cancer Res 2004;10:6282S-6289S
©2004 by American Association for Cancer Research





33



34

Kidney Cancer - Types

- The most common type is clear cell renal cell carcinoma (RCC)
- Clear cell RCC is almost universally characterized by loss of the von Hippel Lindau (VHL) gene
- A familial (autosomal dominant) cancer syndrome of germline VHL mutation can predispose to kidney cancer, although most cases of clear cell RCC as sporadic




W. Marston Linehan et al. Clin Cancer Res 2004;10:6282S-6289S. UNC

35

Kidney Cancer – Risk Factors

| Risk Factor | Comment |
|--------------------------------|-----------------------------|
| Smoking | |
| Hypertension | Dose-response relationship |
| Obesity | Dose-response relationship |
| Acquired cystic kidney disease | Usually dialysis-associated |
| Occupational Exposures | Asbestos, Cadmium, Gasoline |

Others: Familial cancer syndromes, analgesics, hepatitis C, cytotoxic chemotherapy, sickle cell trait (risk for renal medullary carcinoma)

UNC


36

Kidney Cancer – Symptoms

- “Classic triad” of symptoms for RCC:
 - Flank pain
 - Hematuria (blood in the urine)
 - Palpable abdominal mass.

- Other symptoms:
 - Scrotal varicocele
 - Lower extremity edema
 - Ascites

- Tumors can get BIG before they are detected
- Common sites of metastases: lung, lymph nodes, bone, brain



37


Kidney Cancer – Treatment

- Localized = Surgery
 - ie, if you can cut it out, do it

- Metastatic
 - Chemotherapy doesn't work
 - Immunotherapy or targeted therapy



38



39

Testis Cancer in 1 Slide

- Most cases are "germ cell tumors" – meaning they start from the cells that make sperm
- 10,000 new cases per year
- Typically age 20s-40's
- VERY CURABLE
- Orchiectomy (removal of the testicle) cures many
- If has spread to lymph nodes, can get surgery, radiation or chemotherapy depending on type and extent of the cancer
- Advanced disease treated with chemotherapy, which is very effective



40


Supportive Care

- Bone health
 - Drugs (such as those used for osteoporosis)
 - Calcium and Vitamin D
 - Weight Bearing exercise
- Pain control
- Depression/anxiety
- Treatment side effects
 - Nausea control, blood product support, etc
- Grief counseling



41

Oncology drug approvals are skyrocketing.



| Decade | Total NMEs | Annual average |
|-----------|------------|----------------|
| 1951-1960 | 11 | 1.1 |
| 1961-1970 | 17 | 1.7 |
| 1971-1980 | 11 | 1.1 |
| 1981-1990 | 18 | 1.8 |
| 1991-2000 | 44 | 4.4 |
| 2001-2010 | 49 | 4.9 |
| 2011-2013 | 31 | 10.3 |

An analysis of FDA-approved drugs for oncology. Drug Discovery Today 2014 19(12):1631. 

42

Thanks for your attention


Tracy Rose
tracy_rose@med.unc.edu



43

Drug therapy in Genitourinary (GU) cancers

Katie Morgan, PharmD, BCOP, CPP
GU/Neuro Oncology Clinics
University of North Carolina Medical Center



44

Classes of Drugs used in GU cancers

| Traditional Chemotherapy | Targeted therapy | Immuno-therapy | Hormonal therapy | Novel Agents |
|--------------------------|------------------|----------------|------------------|--------------|
| Prostate | Kidney | Kidney | Prostate | Prostate |
| Testicular | Bladder | Bladder | | |
| Bladder | | | | |



45


Traditional Chemotherapy

- Classes of chemotherapy agents
 - Alkylating Agents
 - Antimetabolites
 - Antimicrotubule Agents
 - Topoisomerase inhibitors
 - Other “typical” chemotherapeutics



46

The cell cycle



- G1 - Growth
- S - DNA synthesis
- G2 - Growth and preparation for mitosis
- M - Mitosis (cell division)



47

Cell cycle non-specific agents

- Effects exerted at any phase of the cell cycle
- Toxic effects occur during cell cycle and are expressed during attempt at cell division
- May be more effective given as a bolus dose
 - Examples:
 - Alkylating agents
 - Anthracyclines
 - Platinum agents



48

Cell Cycle specific agents

- Cell Cycle Specific
 - Effect exerted on dividing cells only
 - Not active in resting phase
 - Administration as continuous infusion or multiple divided doses
 - Examples:
 - Antimetabolites
 - Vincas
 - Taxanes
 - Topoisomerase Inhibitors




49

Specific agents used in GU cancers

| Alkylating Agents | Anti-metabolites | Anti-microtubules | Topoisomerase inhibitors | Other |
|-------------------|------------------|-------------------|--------------------------|-------------|
| Cisplatin | Gemcitabine | Docetaxel | Etoposide | Doxorubicin |
| Carboplatin | | Cabazitaxel | | |
| Ifosfamide | Methotrexate | Paclitaxel | | Bleomycin |
| Doxorubicin | | Vinblastine | | |




50

Supportive Care for traditional Chemotherapy

- Chemotherapy induced nausea and vomiting (CINV)
- Myelosuppression
- Mucositis
- Organ toxicity
 - Renal
 - Liver
 - Cardiotoxicity
 - Lung toxicity




51

Targeted Therapy

- Refers to newer generation of agents targeted at cellular processes
 - Monoclonal antibodies
 - Antibody drug conjugates
 - Tyrosine kinase inhibitors
 - Small molecule inhibitors



UNC
UNIVERSITY OF NORTH CAROLINA

52

Monoclonal Antibodies


| | | | |
|--|--|--|--|
|  |  |  |  |
| Murine 100% mouse protein <i>muromonab</i> | Chimeric 33% mouse protein <i>cetuximab, rituximab</i> | Humanized 10% mouse protein <i>bevacizumab, trastuzumab</i> | Human 0% mouse protein <i>panitumumab</i> |

UNC
UNIVERSITY OF NORTH CAROLINA

53

Monoclonal Antibody Mechanism of Action

a Immune-mediated effects of tumour-specific IgG



b Direct effects of tumour-specific IgG



Nature Reviews | Cancer

UNC
UNIVERSITY OF NORTH CAROLINA

54

Antibody Drug Conjugates Mechanism of Action

Key factors:

- High potency
- High cancer cell specificity
- Low immunogenicity
- Long circulating life
- Low cytotoxicity to off-target cells

Source: Toubiani, K., et al. J. Pharm. Med. 2016; DOI: 10.1093/jcp/kmw026

55

Tyrosine Kinase Inhibitors (TKIs) and Small Molecules

Source: Cancer Research UK

56

Targeted Therapy and Downstream Effects

Source: Dr. Asha, A. CA Cancer J Clin 2013;33:206-276

57

Molecular Targets in GU

Kidney

- Vascular endothelial growth factor (VEGF)
- Mammalian target of rapamycin (mTOR)


Bladder

- Fibroblast growth factor receptor (FGFR)
- Nectin-4




58

VEGF Receptor Inhibitors



MABs

- Bevacizumab

TKIs

- Pazopanib
- Axitinib
- Sorafenib
- Sunitinib
- Cabozantinib
- Lenvatinib




59

VEGF Receptor Inhibitors Side Effects

- Target Side Effects
 - Hypertension, heart failure, impaired wound healing, proteinuria, bleeding complications, thrombosis, GI perforation
- Monoclonal Antibodies- infusion reactions
 - Bevacizumab
- Tyrosine Kinase Inhibitors- diarrhea, hand foot syndrome
 - Pazopanib: changes in liver function
 - Sorafenib/Sunitinib: decreased blood counts
 - Axitinib: stomatitis, thyroid disorders
 - Cabozantinib: changes in liver function, thyroid disorders
 - Lenvatinib: thyroid disorders




60

mTOR inhibitors- Everolimus/Temsirolimus

- mTOR inhibitors decrease intracellular signaling downstream of PI3-K/Akt pathway resulting in decreased protein synthesis and apoptosis
- Everolimus- oral mTOR inhibitor
 - Used typically second or third line, monotherapy or in combo with VEGF-Inhibitor
 - Toxicities – mucositis, diarrhea, hyperlipidemia, hyperglycemia, pneumonitis
 - Dexamethasone mouth rinse recommended as prophylaxis
- Temsirolomis – IV mTOR inhibitor
 - Favored in poor risk disease (historically)
 - Toxicities- rash, anemia, nausea, peripheral edema, hyperlipidemia, hyperglycemia

Baskin C, Olin D.C. Therapy 2011;8(4):359-367



61

FGFR inhibitor- Erdafitinib

- Targets gene mutations in FGFR
 - inhibits downstream signaling and tumor growth
- Incidence of FGFR mutations/alterations is about 20% in bladder cancer
- 40% response rates vs. 9% with alternative therapy
- Toxicity
 - Hyperphosphatemia, fatigue, diarrhea, nail toxicity, ocular toxicity, dry mouth, dry eyes, decreased appetite
 - Lubricating eye drops recommended when starting treatment


Gosselin C, et al. Ther Adv Med Oncol. 2019; 11: 175822019842329
Santoro T, et al. J Clin Oncol. 2019; 37(16):2101-2108



62

NECTIN-4 inhibitor- Enfortumab-vedotin


- Nectin involved in polarity, proliferation, differentiation and migration in epithelial, endothelial, immune and nervous systems.
- High expression on bladder cancer cells but low expression in normal tissue
- 40% response rates
- Toxicity
 - Rash, peripheral neuropathy, hyperglycemia, fatigue, diarrhea, nausea, decreased appetite




Kawabata M, et al. J Clin Oncol. 2019; 37(16):2101-2108




63




64




65




66




67



68




69



70

- ### LHRH Agonists and Antagonists
- GnRH Agonists
 - **Leuprolide, histrelin, goserelin, triptorelin**
 - Injections can be given every 1, 3, or 6 months depending on formulation
 - Tumor flare a concern with initial increase in testosterone
 - Can take up to 30 days to reach castration levels of testosterone
 - GnRH Antagonist
 - **Degarelix**
 - SC injection given every 1 month
 - Reduces testosterone to castration levels within 3 days
 - Preferred for patients with advanced disease where testosterone flare would lead to worsening pain, urinary obstruction or spinal cord compression
- Pozzari et al. World J Urol 2019;34:1601-09.
Crawford ED, et al. Prostate Cancer Pharm Clin 2019;2(1):24-34.

71



72

Abiraterone Acetate

- Anti-androgen therapy
- Inhibits steroid 17-hydroxylase/17,20-lyase
- Decreases adrenal androgen synthesis
 - Testosterone → DHT
- Decreases cortisol synthesis
- Results in increased ACTH production and mineralocorticoid excess

www.cabotus.edu

73

Abiraterone Acetate

- Approved in mCSPC and mCRPC with data in high risk localized/nodal disease
- Adverse Events
 - **Mineralocorticoid excess syndrome** (hypertension, hypokalemia, edema)
 - PREDNISON REQUIRED- mimics normal cortisol production and minimizes AEs
 - Dose of 5-10 mg per day
 - Caution in patients with CHF, recent MI, CVD, ventricular arrhythmia
 - Hepatic toxicity requires close monitoring of LFTs for first 3 months
 - Androgen deprivation AEs
- Administration- taken on an empty stomach, fat increases AUC x 10 fold
- Cost- \$12,000/m

Auchincloss et al. Oncologist 2014;19:1231-40.

74

Androgen Receptor Inhibitors

Enzalutamide, Apalutamide, and Darolutamide

- Mechanism of Action
 - Binds to AR receptor
 - inhibits translocation of AR receptor into nucleus
 - inhibits DNA binding and coactivator recruitment
- Common side effects; fatigue, dizziness, hot flashes, arthralgias
- Blood brain barrier penetration; Seizure risk highest with enzalutamide
Enzalutamide > Apalutamide > Darolutamide

Amrarnaghi et al. AJRO 2015;11(2):15-19.

75

Novel Agents for Prostate Cancer

Radium 233


Sipuleucel-T




76

Radium-223 (Xofigo)

- Alpha-emitter calcium mimetic
 - Selectively binds to areas of high bone turnover
 - Induces double stranded DNA breaks
- Treatment of mCRPC with **bone only metastasis**
- ADE- hematologic toxicities, N/V
- Cost - 1000 kBq/mL vial is **\$13,800**
 - One dose could be 4 or more vials x 6 treatments




Nelson et al. Lancet Oncol 2013;369:213-23.




77

Sipuleucel – T (Provenge)

- APCs stimulate T-cell immune response targeted against prostatic acid phosphatase (PAP), which is highly expressed in prostate cancer cells
- Treatment of **asymptomatic or minimally symptomatic** mCRPC
- ADE- infusion related reactions
- Cost- \$93 K (3 doses)



Kantoff et al. NEJM 2010;363:411-22.




78

Sipuleucel – T (Provenge) Process

- Complicated approval and process
 - Application sent to company who then if patient is eligible they do insurance approval
 - Vein assessment by Red cross
 - Peripheral collection vs apheresis catheter
 - Collection via leukapheresis and antigen presenting cells (APCs) isolated ex vivo
 - Sent to Dendreon's manufacturing facility in New Jersey
 - Harvested APCs are incubated with recombinant fusion protein antigen, which contains both PAP and GM-CSF
 - The activated, antigen-loaded APCs are transported back to the infusion center and are infused into the patient
 - From apheresis to administration takes 4 days

Kantoff et al. N Engl J Med 2010;363:411-22
Arzoo et al. PT 2011;36(4):197-202